Matthew Harrison
Stock Analyst at Morgan Stanley
(1.15)
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
VRTX Vertex Pharmaceutica... | Maintains: Equal-Weight | 464 460 | 441.18 | 4.27% | 36 | Jun 20, 2025 | |
SRPT Sarepta Therapeutics | Downgrades: Equal-Weight | 113 40 | 17.1 | 133.92% | 37 | Jun 17, 2025 | |
INSM Insmed | Maintains: Overweight | 90 102 | 99.56 | 2.45% | 17 | Jun 11, 2025 | |
REGN Regeneron Pharmaceut... | Maintains: Overweight | 958 755 | 520.94 | 44.93% | 51 | Jun 2, 2025 | |
GILD Gilead Sciences | Maintains: Overweight | 130 135 | 110.71 | 21.94% | 36 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 6 | 3.44 | 74.42% | 10 | Apr 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 157 152 | 125.95 | 20.68% | 48 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 39 32 | 27.17 | 17.78% | 25 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 82 80 | 34.6 | 131.21% | 11 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 6 5 | n/a | n/a | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 5 | 0.63 | 693.65% | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 41 33 | 14.09 | 134.21% | 12 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 3 | 1.46 | 105.48% | 10 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 4 6 | 1.41 | 325.53% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 8 11 | 13.14 | -16.29% | 9 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 38 8 | 1.21 | 561.16% | 4 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 515 510 | 559.65 | -8.87% | 24 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Equal-Weight | 7 | 2.27 | 208.37% | 18 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 115 112 | 55.12 | 103.19% | 20 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 34 34 | 17.03 | 99.65% | 14 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 32 32 | 20.52 | 55.95% | 27 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 42 38 | n/a | n/a | 6 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 14 4 | n/a | n/a | 6 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 321 319 | n/a | n/a | 27 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 21 19 | 2.42 | 685.12% | 3 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Equal-Weight | 229 229 | n/a | n/a | 23 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Underweight | 60 60 | n/a | n/a | 30 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 21 | n/a | n/a | 7 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 46 | 35.31 | 30.27% | 1 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 12 13 | 7.94 | 63.73% | 4 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 2 1 | 0.74 | 35.14% | 3 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 10 | 19.94 | -49.85% | 9 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 27 8 | 7.08 | 12.99% | 9 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 57 44 | 27.99 | 57.2% | 28 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 19 10 | n/a | n/a | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 13 | 2.83 | 359.36% | 3 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 140 80 | 8.84 | 804.98% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 100 60 | 5.65 | 961.95% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 203 216 | 106.77 | 102.3% | 8 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 5 | 2.7 | 85.19% | 13 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 5 | 1.92 | 160.42% | 6 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 178 182 | 181.89 | 0.06% | 8 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 12 9 | 3.73 | 141.29% | 13 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 30 40 | 56.13 | -28.74% | 6 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 279 282 | 277.28 | 1.7% | 36 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 220 210 | 322.64 | -34.91% | 7 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 736 621 | n/a | n/a | 7 | Sep 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 6 3 | n/a | n/a | 5 | May 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 55 52 | 24.2 | 114.88% | 5 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 175 173 | 152.45 | 13.48% | 3 | Apr 6, 2022 |